FDA’s LDT Proposed Rule Heads to the White House

As discussed in our June Insight, earlier this year FDA publicly announced its development of a proposed rule that would expressly define laboratory developed tests (“LDTs”) as medical devices and subject them to the agency’s regulatory authority. Such a rule would be FDA’s first comprehensive attempt to impose its authority over LDTs since its 2014 draft guidance, which FDA ultimately chose not to finalize, and comes after several failed congressional legislative attempts to do the same….
By: Epstein Becker & Green
Previous Story

Take Two: The Lummis-Gillibrand Crypto Assets Bill 2.0

Next Story

California Court Casts Doubt on Copyright Claims Relating to AI Images